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Treatment of HIV-1 infection with highly active antiretro-
viral therapy (HAART) reduces viremia to below the detec-
tion limit of ultrasensitive clinical assays. However, HIV-1
persists in resting CD4+ T cells and possibly other reser-
voirs. In patients on HAART, HIV-1 persistence is evi-
denced not only by the latent reservoir in resting CD4+ T
cells but also by free virus in the plasma. Given the short
half-life of free virus, this residual viremia indicates active
virus production. This virus production may reflect low-
level ongoing replication that continues despite HAART
and/or release of virus from latently infected cells that
become activated or from other stable cellular reservoirs.
With respect to the issue of drug resistance, it is of partic-
ular importance to determine whether ongoing replica-
tion continues on HAART because the evolution of
resistance can only take place if there are new cycles of rep-
lication. The direct characterization of residual viremia
provides a window into this state of virologic suppression
and a means for determining the importance of different
mechanisms of viral persistence. Characterization of this
residual viremia has been limited because of the technical
difficulties involved in the analysis of extremely low num-
bers of viral RNA templates. To obtain sufficient numbers
of independent viral clones from the plasma of patients
on HAART, we have carried out intensive sampling in a
series of patients and analyzed plasma virus genotypes
with a sensitive RT-PCR method. Viral variants in the
plasma were compared to viruses in the latent reservoir.
The results provided evidence that in some patients on
HAART, much of the residual viremia is due to continued
production of a small number of viral clones over pro-
longed periods without evident sequence change by cells
that are not well represented in the circulation. The static
nature of the residual viremia is not consistent with ongo-
ing viral replication. These results have implications for
understanding HIV-1 persistence and treatment failure.
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